Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Vectibix; Belgium: Vectibix; Bulgaria: Vectibix; Cyprus: Vectibix; Czech Republic: Vectibix; Denmark: Vectibix; Estonia: Vectibix; Finland: Vectibix; France: Vectibix; Germany: Vectibix; Greece: Vectibix; Hungary: Vectibix; Ireland: Vectibix; Italy: Vectibix; Latvia: Vectibix; Lithuania: Vectibix; Malta: Vectibix; Poland: Vectibix; Portugal: Vectibix; Romania: Vectibix; Slovakia: Vectibix; Slovenia: Vectibix; Spain: Vectibix; Sweden: Vectibix; UK: Vectibix.

North America

Canada: Vectibix; USA: Vectibix.

Drug combinations


Panitumumab: C~6398~H~9878~N~1694~O~2016~S~48~. Mw: approx. 144.32. (1) Immunoglobulin, anti-(human epidermal growth factor receptor)(human monoclonal ABX-EGF heavy chain), disulfide with human monoclonal ABX-EGF light chain, dimer; (2) Immunoglobulin, human (anti-human epidermal growth factor receptor) monoclonal antibody (ABX-EGF). CAS-339177-26-3 (2004).

Pharmacologic Category

Other Antineoplastic Agents; Monoclonal Antibodies. Epidermal Growth Factor Receptor Inhibitor. (ATC-Code: L01XC08).

Mechanism of action

Recombinant human IgG~2~ monoclonal antibody which binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) and competitively inhibits binding of epidermal growth factor and other ligands. Binding to EGFR blocks phosphorylation and activation of intracellular tyrosine kinases, resulting in inhibition of cell survival, growth, proliferation and transformation.

Therapeutic use

Monotherapy in treatment of refractory metastatic colorectal cancer.

Pregnancy and lactiation implications

Animal reproductive studies demonstrated adverse fetal effects. IgG known to cross placenta; therefore, it is possible developing fetus may be exposed to panitumumab. Panitumumab should only be given to pregnant woman if potential benefit justifies potential risk to fetus. Not recommended during lactation.

Unlabeled use


None known to date.

Warnings and precautions

Dermatologic toxicities reported (may include dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin and skin fissures). May exacerbate skin reactions. Gastric mucosal, ocular and nail toxicities also reported. May cause diarrhea (use with combination chemotherapy regimens not recommended). Electrolyte depletion (hypomagnesemia and hypocalcemia) may occur. Severe infusion reactions (anaphylactic reaction, bronchospasm, chills, fever, hypotension) reported in ~1% of patients. Pulmonary fibrosis reported (rarely)(use caution with lung disease). Panitumumab not indicated for use in combination with chemotherapy.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart